Your session is about to expire
← Back to Search
Monoclonal Antibodies
Risankizumab for Ulcerative Colitis (COMMAND Trial)
Phase 3
Waitlist Available
Research Sponsored by AbbVie
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Must not have
Participants who have a known hypersensitivity to risankizumab or the excipients of any of the study drugs or the ingredients of chinese hamster ovary (CHO) or had an adverse event (AE) during Studies M16-067 that in the Investigator's judgment makes the participant unsuitable for this study.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to week 300
Awards & highlights
Pivotal Trial
Summary
This trial will assess the safety and efficacy of risankizumab as a treatment for ulcerative colitis. The study will last for 52 weeks and will compare the results of those taking risankizumab to those taking a placebo.
Who is the study for?
This trial is for people with ulcerative colitis who responded to risankizumab in a previous study. They must not have allergies to risankizumab, its ingredients, or substances from Chinese hamster ovary cells. Participants should be compliant with medication requirements from the prior study.
What is being tested?
The trial tests the safety and effectiveness of risankizumab over 52 weeks compared to a placebo. It includes three sub-studies: one double-blind controlled study, one exploratory study, and an open-label extension for certain participants affected by COVID-19 or geopolitical issues.
What are the potential side effects?
While specific side effects are not listed here, potential risks may include allergic reactions to risankizumab or its components. Side effects experienced in the earlier phase of the trial could also be relevant.
Eligibility Criteria
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I am not allergic to risankizumab, its ingredients, or products from Chinese hamster ovary cells.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to week 300
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to week 300
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Percentage of Participants with Adverse Events (AE)
Sub-Study 1: Percentage of Participants Achieving Clinical Remission per Adapted Mayo Score
Secondary study objectives
Sub-Study 1: Change in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue)
Sub-Study 1: Change in Inflammatory Bowel Disease Questionnaire (IBDQ)
Sub-Study 1: Change in Number of Days per Week with Sleep Interrupted due to UC Symptoms
+14 moreSide effects data
From 2020 Phase 3 trial • 18 Patients • NCT0302204550%
Dehydration
25%
Inflammation
25%
Constipation
25%
Acne
25%
Pyrexia
25%
Pain in extremity
25%
Gastric cancer
25%
Alcoholic liver disease
25%
Hypoglycaemia
25%
Abdominal pain upper
25%
Vomiting
25%
Hepatic function abnormal
25%
Decreased appetite
25%
Depression
25%
Ear infection
25%
Viral upper respiratory tract infection
25%
Haemorrhage subcutaneous
25%
Rash
100%
80%
60%
40%
20%
0%
Study treatment Arm
GPP Risankizumab 150 mg
EP Risankizumab 150 mg
GPP Risankizumab 75 mg
EP Risankizumab 75 mg
Awards & Highlights
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
Trial Design
8Treatment groups
Experimental Treatment
Placebo Group
Group I: Substudy 3: OL Extension RisankizumabExperimental Treatment1 Intervention
Participants who completed Sub-study 1 or 2 receive open-label risankizumab in Sub-study 3.
Group II: Substudy 2: Open-label (OL) Clinical Assessment RisankizumabExperimental Treatment1 Intervention
Participants randomized to receive risankizumab dose 1 administered by subcutaneous (SC) injection.
Group III: Substudy 2: OL Therapeutic Drug Monitoring RisankizumabExperimental Treatment1 Intervention
Participants randomized to receive risankizumab dose 1 administered by subcutaneous (SC) injection.
Group IV: Substudy 1: Double-blind Risankizumab Dose 2Experimental Treatment1 Intervention
Participants randomized to receive risankizumab dose 2 administered by subcutaneous (SC) injection.
Group V: Substudy 1: Double-blind Risankizumab Dose 1Experimental Treatment1 Intervention
Participants randomized to receive risankizumab dose 1 administered by subcutaneous (SC) injection.
Group VI: OL Continuous Treatment Extension - Dose 2Experimental Treatment1 Intervention
Participants who complete Sub-study 3 and continue to tolerate and derive benefit from receiving risankizumab, will continue to receive risankizumab based on their assignment during Sub-study 3. Participants completing Sub-study 3 and received risankizumab rescue therapy in any sub-study will receive risankizumab Dose 2 administered by subcutaneous (SC) injection.
Group VII: OL Continuous Treatment Extension - Dose 1Experimental Treatment1 Intervention
Participants who complete Sub-study 3 and continue to tolerate and derive benefit from receiving risankizumab, will continue to receive risankizumab based on their assignment during Sub-study 3. Participants completing Sub-study 3 without receiving risankizumab rescue therapy in any sub-study will receive risankizumab Dose 1 administered by subcutaneous (SC) injection.
Group VIII: Substudy 1: Double-blind PlaceboPlacebo Group1 Intervention
Participants randomized to receive placebo for risankizumab administered by subcutaneous (SC) injection.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
risankizumab
2016
Completed Phase 3
~5570
Find a Location
Who is running the clinical trial?
AbbVieLead Sponsor
1,023 Previous Clinical Trials
519,047 Total Patients Enrolled
18 Trials studying Ulcerative Colitis
6,067 Patients Enrolled for Ulcerative Colitis
ABBVIE INC.Study DirectorAbbVie
444 Previous Clinical Trials
159,533 Total Patients Enrolled
9 Trials studying Ulcerative Colitis
3,021 Patients Enrolled for Ulcerative Colitis
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I am not allergic to risankizumab, its ingredients, or products from Chinese hamster ovary cells.
Research Study Groups:
This trial has the following groups:- Group 1: OL Continuous Treatment Extension - Dose 2
- Group 2: Substudy 1: Double-blind Risankizumab Dose 2
- Group 3: Substudy 3: OL Extension Risankizumab
- Group 4: Substudy 2: OL Therapeutic Drug Monitoring Risankizumab
- Group 5: Substudy 2: Open-label (OL) Clinical Assessment Risankizumab
- Group 6: OL Continuous Treatment Extension - Dose 1
- Group 7: Substudy 1: Double-blind Placebo
- Group 8: Substudy 1: Double-blind Risankizumab Dose 1
Awards:
This trial has 1 awards, including:- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Share this study with friends
Copy Link
Messenger